167 related articles for article (PubMed ID: 23543607)
1. Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.
Nasr M
AAPS PharmSciTech; 2013 Jun; 14(2):719-26. PubMed ID: 23543607
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of microcrystals for enhanced dissolution rate of celecoxib.
Lakshmi K; Reddy MP; Kaza R
Curr Drug Discov Technol; 2013 Dec; 10(4):305-14. PubMed ID: 24074306
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles.
Liu Y; Sun C; Hao Y; Jiang T; Zheng L; Wang S
J Pharm Pharm Sci; 2010; 13(4):589-606. PubMed ID: 21486533
[TBL] [Abstract][Full Text] [Related]
4. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
5. Spherical crystals of celecoxib to improve solubility, dissolution rate and micromeritic properties.
Gupta VR; Mutalik S; Patel MM; Jani GK
Acta Pharm; 2007 Jun; 57(2):173-84. PubMed ID: 17507314
[TBL] [Abstract][Full Text] [Related]
6. Preparation and physicochemical and preclinical evaluations of recrystallized celecoxib.
Mutalik S; Usha N; Ranjith AK; Umesh S; Musmade P; Anup N
PDA J Pharm Sci Technol; 2007; 61(5):362-74. PubMed ID: 18047175
[TBL] [Abstract][Full Text] [Related]
7. In situ intestinal permeability and in vivo oral bioavailability of celecoxib in supersaturating self-emulsifying drug delivery system.
Song WH; Yeom DW; Lee DH; Lee KM; Yoo HJ; Chae BR; Song SH; Choi YW
Arch Pharm Res; 2014 May; 37(5):626-35. PubMed ID: 23852645
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo characteristics of celecoxib in situ formed suspensions for intra-articular administration.
Larsen SW; Frost AB; Ostergaard J; Thomsen MH; Jacobsen S; Skonberg C; Hansen SH; Jensen HE; Larsen C
J Pharm Sci; 2011 Oct; 100(10):4330-7. PubMed ID: 21598256
[TBL] [Abstract][Full Text] [Related]
9. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process.
Ha ES; Choo GH; Baek IH; Kim MS
Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246
[TBL] [Abstract][Full Text] [Related]
10. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
Jain SK; Gupta Y; Jain A; Bhola M
Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib-cyclodextrin systems: characterization and evaluation of in vitro and in vivo advantage.
Nagarsenker MS; Joshi MS
Drug Dev Ind Pharm; 2005 Jan; 31(2):169-78. PubMed ID: 15773284
[TBL] [Abstract][Full Text] [Related]
12. Microbeads: a novel multiparticulate drug delivery technology for increasing the solubility and dissolution of celecoxib.
McDonald BF; Coulter IS; Marison IW
Pharm Dev Technol; 2015 Mar; 20(2):211-8. PubMed ID: 24283499
[TBL] [Abstract][Full Text] [Related]
13. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
14. Design and evaluation of celecoxib porous particles using melt sonocrystallization.
Paradkar A; Maheshwari M; Kamble R; Grimsey I; York P
Pharm Res; 2006 Jun; 23(6):1395-400. PubMed ID: 16741659
[TBL] [Abstract][Full Text] [Related]
15. The mechanism for increasing the oral bioavailability of poorly water-soluble drugs using uniform mesoporous carbon spheres as a carrier.
Wang T; Zhao P; Zhao Q; Wang B; Wang S
Drug Deliv; 2016; 23(2):420-8. PubMed ID: 24870199
[TBL] [Abstract][Full Text] [Related]
16. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug.
Morgen M; Bloom C; Beyerinck R; Bello A; Song W; Wilkinson K; Steenwyk R; Shamblin S
Pharm Res; 2012 Feb; 29(2):427-40. PubMed ID: 21863477
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical characterization and in vitro dissolution behaviour of celecoxib-beta-cyclodextrin inclusion complexes.
Sinha VR; Anitha R; Ghosh S; Amita ; Kumria R; Bhinge JR; Kumar M
Acta Pharm; 2007 Mar; 57(1):47-60. PubMed ID: 19839406
[TBL] [Abstract][Full Text] [Related]
18. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
19. Assessment of absorption potential of poorly water-soluble drugs by using the dissolution/permeation system.
Kataoka M; Yano K; Hamatsu Y; Masaoka Y; Sakuma S; Yamashita S
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1317-24. PubMed ID: 23811221
[TBL] [Abstract][Full Text] [Related]
20. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
